These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36532056)

  • 21. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
    Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With
    Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y
    JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
    Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
    Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
    Kang S; Jeong H; Park JE; Kim HS; Kim YH; Lee DH; Kim SW; Lee JC; Choi CM; Yoon S
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4523-4532. PubMed ID: 36136277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer.
    Bote H; Mesas A; Baena J; Herrera M; Paz-Ares L
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):289-300. PubMed ID: 36203360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
    La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST
    Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.
    Chang J; Jing X; Hua Y; Geng K; Li R; Lu S; Zhu H; Zhang Y
    J Cancer Res Clin Oncol; 2023 May; 149(5):1825-1833. PubMed ID: 35737093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.
    Wang W; Lin G; Hao Y; Guan Y; Zhang Y; Xu C; Wang Q; Wang D; Jiang Z; Cai J; Lou G; Song Z; Zhang Y
    Eur J Cancer; 2022 Oct; 174():21-30. PubMed ID: 35970032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
    Hosokawa S; Ichihara E; Bessho A; Harada D; Inoue K; Shibayama T; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 Feb; 51(2):279-286. PubMed ID: 33049757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: A case report.
    Zhang QN; Li Y; Zhao Q; Tian M; Chen LL; Miao LY; Zhou YJ
    Thorac Cancer; 2021 May; 12(10):1617-1619. PubMed ID: 33760389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
    Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
    Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.